Lifeward Ltd. filings document regulatory disclosures for a Nasdaq-listed medical technology company whose ordinary shares trade under LFWD. The filing record includes Form 8-K material-event reports, annual-report references, shareholder vote results, and disclosures tied to its rehabilitation and recovery technology business.
Recent filings cover a completed acquisition, related ordinary-share and warrant consideration, a reverse share split, amendments to articles of association, authorized share-capital changes, and Nasdaq listing-compliance matters. The filings also document board and audit committee governance, officer employment and compensation arrangements, operating and financial results, material agreements, risk factors, and clinical or regulatory disclosures.
Lifeward Ltd. Chief Medical Officer Rose Keith Dale filed an initial Form 3 reporting her equity position in the company. The filing lists direct ownership of 2,083 ordinary shares of no par value as of May 1, 2026, and does not report any share purchases or sales.
Lifeward Ltd. appointed Keith D. Rose, M.D. as its Chief Medical Officer, effective May 1, 2026. He has served in several senior medical affairs roles at the company since March 2023, most recently as Vice President, Medical Affairs, Medical Director – Neurosciences.
Before joining Lifeward, Dr. Rose held medical leadership positions at Biocodex, Novocure, Ipsen, Jazz Pharmaceuticals and Indivior. He earned his medical degree with distinction from The George Washington University and completed a five-year residency in Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine.
Lifeward Ltd. notified the SEC it cannot file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 on time and expects to file within five calendar days. The delay is to complete accounting and valuation work related to a Strategic Transaction completed on March 25, 2026. The company provided preliminary results: a $1.1 million (approximately 22%) decline in revenue and an expected increase in net loss of $6.0 million (approximately 123%) versus the three months ended March 31, 2025. The revenue decline is tied to an ~$1.3 million drop in AlterG revenue from lower unit shipments; the larger loss primarily reflects a $4.9 million one-time research and development charge related to acquired in-process R&D and $0.6 million of financing and derivative remeasurement expenses. These figures are preliminary and subject to change when the Form 10-Q is finalized.
Lifeward Ltd. reported first quarter 2026 revenue of $3.9 million, down from $5.0 million a year earlier, mainly due to lower AlterG shipments tied to working capital constraints. Gross margin fell to 34.2% from 42.2% on lower production volumes and higher tariffs.
GAAP net loss widened to $10.8 million or $6.70 per share, driven by a one-time, non-cash $4.9 million in-process R&D charge and other transaction-related expenses. On a non-GAAP basis, net loss was $5.1 million, similar to last year. Cash and cash equivalents rose to $11.4 million, helped by convertible note financing and $6.5 million of cash from the Oratech acquisition.
The company closed its strategic transaction with Oramed, completed a $10 million financing, acquired Oratech and upper body exoskeleton technology, and reduced quarterly operating cash burn by 33% year-over-year. Lifeward also disclosed it will delay filing its Form 10-Q for the quarter as it finalizes accounting for the March 2026 transaction.
Oramed Pharmaceuticals Inc. has filed an initial ownership report for Lifeward Ltd., showing it as a ten-percent owner. Oramed directly holds 1,250,363 ordinary shares. It also holds senior secured convertible notes and several warrant series that can convert into additional ordinary shares, subject to strict ownership caps.
The notes are convertible into 1,666,666 ordinary shares at an exercise price of $5.4000 per share. Oramed also holds share purchase warrants for 1,666,666 and 1,296,296 ordinary shares at $5.4000, plus pre-funded warrants for 1,006,113 ordinary shares at a $0.0000 exercise price. Footnotes state these instruments generally cannot be exercised if conversion would give Oramed more than 49.99% or 45.0% beneficial ownership of Lifeward’s ordinary shares.
Oramed Pharmaceuticals Inc. has filed a Schedule 13D reporting beneficial ownership of 1,528,221 Lifeward Ltd. ordinary shares, representing 49.9% of the class. This stake arises from Lifeward’s acquisition of Oramed’s subsidiary Oratech and a related financing.
At closing of the share purchase, Lifeward issued 1,250,363 ordinary shares, Pre-Funded Warrants for up to 1,006,113 shares at an exercise price of $0.0001 per share, and Share Purchase Warrants for up to 1,296,296 shares at an initial exercise price of $5.40 per share. Oramed also purchased senior secured convertible notes with $9,000,000 principal amount, initially convertible at $5.40 per share, and Purchase Agreement Warrants for up to 1,666,666 shares at $5.40 per share.
The Pre-Funded Warrants and Share Purchase Warrants are subject to a 49.99% beneficial ownership limitation, and the notes and Purchase Agreement Warrants have a 45.0% beneficial ownership limitation. Oramed also receives 4% Revenue Sharing Payments on specified ReWalk Personal Exoskeleton net revenue, subject to caps and a term of up to 10 years or until Lifeward reaches a $200 million market capitalization.
Lifeward Ltd. has filed a prospectus for the resale by selling shareholders of up to 7,256,474 ordinary shares. The shares consist of issued shares and shares issuable upon exercise or conversion of a pre-funded warrant, transaction warrant, initial warrants and convertible notes issued in connection with the Strategic Acquisition.
The company is not selling shares here and will receive no proceeds from resales; selling shareholders will pay resale commissions. The prospectus cites a last reported sale price of $7.38 per share on April 24, 2026 and discloses certain shareholder ownership limits and plan‑of‑distribution methods.
Lifeward Ltd. has given notice that the employment of Jeannine Lynch, its Vice President of Strategy and Market Access, will be terminated effective May 3, 2026. The departure is being treated as a termination without cause under her Employment Agreement dated July 9, 2021.
Ms. Lynch will receive severance and other benefits in line with that Employment Agreement. The company previously described the terms of this agreement in its Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 18, 2026.
Lifeward Ltd. director Sigsbee William Mark reported an equity compensation grant. He received 11,485 ordinary shares in the form of restricted stock units at a price of $0.00 per share, bringing his direct holdings reported in this filing to 11,485 shares.
The 11,485 RSUs were granted on March 25, 2026 under Lifeward’s 2025 Incentive Compensation Plan. These RSUs vest in four equal quarterly installments, starting three months after the grant date, meaning the award converts into shares gradually over a one‑year period if service conditions are met.